 Glibenclamide reduces space occupying edema and brain swelling following cerebral ischemia.
administered anti-Abcc8/SUR1 or anti-Trpm4/TRPM4 AS-ODN, hemispheric swelling was significantly less, 11.63.9% and 12.85.8% respectively (P<0.0001), and the relationship between infarct volume and swelling was reduced and not significant. AS-ODNs directed against Kcnj8/KIR6. 1 and Kcnj11/KIR6.2 had no significant effect on hemispheric swelling (23.35.4% and 22.95.8% respectively). Post-ischemic tissues showed co-assembly of SUR1-TRPM4 heteromers.
Conclusions.
Post-ischemic hemispheric swelling can be decoupled from infarct volume. SUR1-TRPM4 channels, not KATP, mediate post-ischemic brain swelling.
Abbreviations:
AS-ODN, antisense oligodeoxynucleotide ATP, adenosine triphosphate BBB, blood-brain barrier ischemia. The harmful, often fatal effects of brain swelling are well known in patients with large hemispheric (malignant) infarction (LHI) [2, 5] , but swelling also may complicate smaller strokes.
Recent evidence indicates that swelling is an independent predictor of poor outcome in nonmalignant strokes, with a swelling volume of only 11 mL being the threshold with the greatest sensitivity and specificity for predicting poor outcome [4] .
Glibenclamide was first shown to reduce cerebral edema (excess tissue water) in a rodent model of LHI [27] . Subsequent work with different models of LHI confirmed that glibenclamide reduces ischemic brain swelling and its associated high mortality [28] [29] [30] . In rodent models of both fatal (malignant) and non-fatal stroke, reducing edema by treatment with glibenclamide is accompanied by improved neurological scores [28] [29] [30] 38] . Data from two phase 2 clinical trials showed that intravenous glibenclamide reduces edema and brain swelling in patients with LHI [12, 13, 25, 26, 35] .
Glibenclamide is a potent inhibitor of numerous ion channels that are regulated by sulfonylurea receptor (SUR), including four molecularly distinct KATP channels (SUR1-KIR6.2, SUR2A-KIR6.2, SUR2B-KIR6.2, SUR2B-KIR6.1) [24, 33, 34] , as well as SUR1-TRPM4 channels [27, 40] . Here, we sought to determine which of these ion channels might be the target of glibenclamide in post-ischemic brain swelling. We employed a strategy of gene suppression of the various ion channel subunits using intravenous antisense oligodeoxynucleotides (AS-ODNs), which exhibit augmented efficacy at low pH [10] , as found in ischemic brain [18] . We J o u r n a l P r e -p r o o f studied a permanent middle cerebral artery occlusion (pMCAo) model, in which swelling is robust but generally non-lethal [32, 37] . Here, we report that suppressing Abcc8/SUR1 and Trmp4/TRPM4, but not Kcnj8/KIR6.1 or Kcnj11/KIR6.2, was highly effective in reducing hemispheric swelling, consistent with involvement of SUR1-TRPM4, not KATP.
METHODS

Ethics statement.
We certify that all applicable institutional and governmental regulations concerning the ethical use of animals were followed during the course of this Corp, Redlands CA) and laser Doppler flowmetry to assure >75% reduction in relative cerebral blood flow, as we described [30, 31] .
Treatments. In three series of experiments, pMCAo rats were randomly assigned to receive either AS-ODN targeting a channel subunit, or scrambled ODN (Scr-ODN) or sense ODN (SE-ODN) as control, including series 1: AS-ODN targeting Abcc8/SUR1 (12 rats, with 13
Scr-ODN controls); series 2: Trpm4/TRPM4 (13 rats, with 16 SE-ODN controls); series 3: Kcnj8/KIR6.1 (7 rats) or Kcnj11/KIR6.2 (7 rats), with 5 Scr-ODN controls. Rat anti-Abcc8/SUR1 (5′-GGCCGAGTGGTTCTCGGT-3′), anti-Trpm4/TRPM4 (5'-TTGTGGTAACACTCTCCAAA-3') and anti-Kcnj11/KIR6.2 (5'-CCTTTCGGGACAGCATGGCT-3') AS-ODNs were described previously [9] . Rat anti-Kcnj8/KIR6.1 AS-ODN (5'-TCTTCCTGGCCAGCATCTTC-3'), which targets the translation initiation codon [7] , was newly designed for the present study. ODNs, J o u r n a l P r e -p r o o f which were phosphorothioated at 4 distal bonds at both the 5' and 3' ends to protect against endogenous nucleases [8] , were obtained commercially (Sigma-Aldrich). Prior to surgery, miniosmotic pumps (Alzet 2001D, 8 µL/hour; Durect Corp.) fitted with jugular vein catheters were loaded with ODN and primed. ODN solutions were prepared in sterile normal saline (NS) (4 mg/mL). Immediately after pMCAo, the jugular vein was catheterized, a loading dose of ODN (400 g in 100 L) was administered intravenously (IV), and the pump catheter was inserted into the jugular vein with the pump implanted subcutaneously in the dorsal thorax, to obtain IV delivery of ODN at a rate of 32 g / hour until euthanasia, yielding a total dose delivered of ~1.2 mg / 24 hours.
Neurofunction. At 24 hours, neurological function was evaluated by investigators
blinded to treatment group using an 8-point neuroscore system (8, stroke-related death; 7, no response to stimulation; 6, ambulate only when stimulated; 5, circle or ambulate spontaneously only to the left; 4, spontaneous movements in all directions with circling to the left exhibited only if pulled by the tail; 3, reduced resistance to lateral push toward the left side; 2, left shoulder adduction when suspended by the tail; 1, left forelimb flexion when suspended by the tail, or failure to extend the right forepaw fully; 0, no neurological deficit), as we described [29] . Here, for analysis, scores were dichotomized at 5/6 based on the presence or absence of spontaneous movements. This threshold has high interobserver reliability, and was found previously to distinguish between treatment groups in the same pMCAo model [38] .
Infarct volume and hemispheric swelling.
After evaluation of neurological function, rats were euthanized. Six coronal sections, 2 mm thick, were used to determine infarct volumes using 2,3,5-triphenyltetrazolium chloride (TTC), corrected for swelling, as described [16] , and to determine hemispheric swelling, as described [16] .
Exclusions.
A total of 86 rats underwent pMCAo. Of these, 3 were excluded prior to randomization for LDF <75%; 3 rats died after randomization, prior to planned euthanasia at 24 J o u r n a l P r e -p r o o f hours; 7 rats were excluded for TTC-infarct volumes <40%. These exclusions left 73 rats as the basis for this report, with group assignments detailed above (see "Treatments").
Immunohistochemistry, immuno-FRET and co-immunoprecipitation. These
procedures were performed using custom anti-SUR1 and anti-TRPM4 antibodies, as we described [9, 40] . 
RESULTS
Infarct volume
Rats underwent pMCAo and were randomly assigned to receive AS-ODNs directed against Abcc8/SUR1, Trpm4/TRPM4, Kcnj8/KIR6.1 or Kcnj11/KIR6.2, with sense or scrambled ODNs used as controls. In the combined control groups, TTC infarct volumes at 24 hours were 57.48.8% (n=34) of the hemisphere (Fig. 1) [38] , and were not different between individual control groups (P=1) ( Fig. 2A ). In the four groups treated with AS-ODNs, infarct volumes were unchanged compared to controls (P=1) (Fig. 1, 2A) .
Hemispheric swelling
In the combined control groups, hemispheric swelling at 24 hours was 23.94.1% (n=34) [38] , and was not different between individual control groups (P=1) ( Fig. 2B ). Of the four groups J o u r n a l P r e -p r o o f treated with AS-ODNs, compared to controls, hemispheric swelling was significantly decreased by anti-Abcc8/SUR1 (P<0.0001) and anti-Trmp4/TRPM4 AS-ODN (P<0.0001) ( Fig. 1, 2B ), but not by anti-Kcnj8/KIR6.1 (P=1) or anti-Kcnj11/KIR6.2 (P=1) AS-ODN (Fig. 2B ).
In the combined control groups, linear regression showed that hemispheric swelling was significantly related to infarct volume (P<0.02) (Fig. 2C) . By contrast, in rats administered anti-Abcc8/SUR1 and anti-Trmp4/TRPM4 AS-ODN, the regression line was shifted downward, and the slope was not significantly different from zero.
Neuroscores, dichotomized according to the presence or absence of spontaneous movements, reflected hemispheric swelling. Significantly greater proportions of rats exhibited spontaneous movements that had been administered anti-Abcc8/SUR1 or anti-Trmp4/TRPM4
AS-ODN, compared to Scr-ODN, SE-ODN, anti-Kcnj8/KIR6.1 AS-ODN, or anti-Kcnj11/KIR6.2 AS-ODN (Fig. 2D ).
SUR1-TRPM4 heterodimers
Analysis of post-ischemic brain tissues showed de novo upregulation of SUR1 and TRPM4, which colocalized in microvessels, and which co-assembled into heteromers, as indicated by immuno-FRET ( Fig. 3A-F ). Co-immunoprecipitation confirmed the co-assembly of SUR1-TRPM4 heteromers, with quantification showing a >10-fold increase post-ischemia ( Fig.   3G ).
DISCUSSION
Glibenclamide is a potent inhibitor of four molecularly distinct KATP channels, SUR1-KIR6.2, SUR2A-KIR6.2, SUR2B-KIR6.2 and SUR2B-KIR6.1, some of which are expressed constitutively by various cell types in the brain [24, 33, 34] . Glibenclamide also is a potent inhibitor of SUR1-TRPM4 channels, which are not constitutively expressed, but are transcriptionally upregulated in all members of the neurovascular unit following cerebral J o u r n a l P r e -p r o o f ischemia [27, 39, 40] . In the case of these 5 ion channels, glibenclamide inhibits channel function by targeting the regulatory subunit, SUR. In addition, glibenclamide inhibits the NODlike receptor pyrin domain containing 3 (NLRP3) inflammasome, an effect that is independent of KATP or SUR [43] .
Historically, glibenclamide was considered to be a specific inhibitor of KATP, and so effects of glibenclamide post-ischemia, both favorable and potentially unfavorable, often were assumed to be due to blockade of KATP. Because KATP channels are reported to protect neurons from ischemia [33, 34] , and to play an important role in ischemic preconditioning [3, 6] , questions arose about potentially harmful effects of administering glibenclamide post-ischemia.
However, multiple reports have appeared demonstrating that post-ischemic administration of glibenclamide is beneficial. Glibenclamide inhibition of KATP, at least in theory, is said to reduce ATP consumption that would be required to replenish intracellular K + extruded via KATP in post-ischemic neurons [19] . Glibenclamide favorably influences microglial function, enhances neurogenesis, and improves neurological outcome post-ischemia, with these effects attributed to KATP blockade [20] [21] [22] . Glibenclamide ameliorates ischemia-reperfusion injury via modulating oxidative stress and inflammation [1] . In non-lethal rat models of stroke, glibenclamide reduces infarct volume [31, 38] , in lethal rat models, glibenclamide reduces brain swelling and death [27] [28] [29] [30] 44] , and in both non-lethal and lethal models, glibenclamide improves neurological outcome [28-30, 38, 42, 44] . Moreover, data from two phase 2 clinical trials show that intravenous glibenclamide reduces edema and brain swelling in patients with LHI [12, 13, 25, 26, 35] .
In the last series of studies, the effects of glibenclamide were attributed not to KATP, but to SUR1-TRPM4. The initial work reporting involvement of SUR1-TRPM4 channels (at the time, named SUR1-regulated NCCa-ATP channels) in cerebral ischemia used patch clamp techniques to show that post-ischemic neurons express ion channels with the biophysical properties of SUR1-TRPM4, not KATP [27] . Support for involvement of SUR1-TRPM4 came from subsequent J o u r n a l P r e -p r o o f work on post-mortem tissues from humans with stroke, in which immuno-FRET was used to demonstrate co-assembly of SUR1-TRPM4 heteromers in all cell types of the neurovascular unit [17] . Support for involvement of TRPM4 came from work with a murine model of stroke, in which global gene deletion of Trpm4 yielded a 2-fold reduction in infarct volume and substantial recovery of motor function [15] .
Here, we provide evidence that SUR1-TRPM4 is a critical target of glibenclamide in cerebral ischemia. The outcome measure that we studiedhemispheric swellingwas shown to be linked to SUR1-TRPM4, not KATP, based on experiments with molecularly specific AS-ODNs that targeted four channel subunits individually. Our experiments showed that hemispheric swelling was significantly reduced by AS-ODNs directed against Abcc8/SUR1 and Trpm4/TRPM4, but not Kcnj8/KIR6.1 or Kcnj11/KIR6.2, consistent with involvement of SUR1-TRPM4, not KATP, in post-ischemic brain swelling. Moreover, we showed here, as previously [17] , that SUR1-TRPM4 heteromers co-assemble in post-ischemic tissues, consistent with the formation of functional SUR1-TRPM4 channels. The present results are arguably the strongest to date to distinguish between SUR1-TRPM4 and KATP, and to implicate SUR1-TRPM4 in postischemic cerebral edema.
The effect on hemispheric swelling of anti-Abcc8/SUR1 AS-ODN found here resembles closely the effect of glibenclamide in the same pMCAo model reported by an independent group, Wali et al. [38] . In both studies, control pMCAo rats showed 50-60% infarct volumes and 20-25% hemispheric swelling, and in both studies, swelling was reduced by approximately half, to 10-15% by treatments that targeted SUR1, either glibenclamide or anti-Abcc8/SUR1 AS-ODN. The major difference between the two studies was on infarct volume. Whereas the previous study by Wali et al. [38] , as well as a report by us with the same model [31] , showed significant reductions in infarct volumes with glibenclamide, here we found no effect of anti-Abcc8/SUR1 AS-ODN on infarct volume. Whether the lack of effect on infarct size with ODN reflects differential blood-brain barrier (BBB) penetration of ODN vs. drug, or some other J o u r n a l P r e -p r o o f difference, remains to be resolved.
It is generally accepted that infarct volume predicts hemispheric swelling [14, 31] . Most studies on treatments found to reduce post-ischemic edema are difficult to interpret regrading edema per se, since in most cases, the treatment also reduced infarct volume. By contrast, in the present study, the AS-ODNs that reduced hemispheric swelling had no effect on infarct volume, obviating this important confounder. In pMCAo rats administered control ODNs, we found a statistically significant positive correlation between infarct volume and hemispheric swelling, whereas in rats treated with AS-ODNs targeting Abcc8/SUR1 and Trpm4/TRPM4, this relationship was lost, with the regression line shifted downward and the slope no longer significantly different from zero. To our knowledge, this is the first demonstration of frank decoupling of brain swelling from infarct volume.
Apart from hemispheric swelling [16] , which we studied here, measures of edema reported in preclinical studies include excess tissue water, extravasation of endogenous or exogenous blood-borne molecules, tissue density by computed tomography, and relative diffusivity of water by magnetic resonance imaging. Excess tissue water has been criticized as potentially misleading, since small changes in percent water content actually reflect much larger changes in brain swelling [11] . Midline shift, which is used frequently in human studies [23] , is used only rarely in preclinical studies, although it correlates well with excess tissue water [36] .
Our preference for hemispheric swelling is based on the simplicity and reliability of this measurement, and its ability to convey the clinically relevant concepts of space-occupying edema and mass effect that give rise to neurological dysfunction.
This study has limitations. Although AS-ODNs offer a high degree of molecular specificity, they have limited penetration into the brain, owing to the negligible transport of these highly polar molecules across the BBB [41] . AS-ODNs are devoid of cellular specificity, and thus our data cannot address which element of the microvascular BBB complexendothelium, pericyte, or astrocyte endfootis involved in SUR1-mediated post-ischemic brain swelling. Our J o u r n a l P r e -p r o o f experiments focused on brain swelling and its neurofunctional consequence, but did not examine microglial function, neurogenesis, oxidative stress, or inflammation, which also are reported to benefit from glibenclamide treatment post-ischemia. Thus, our conclusion on involvement of SUR1-TRPM4 in brain swelling cannot, without further study, be extended to these other domains.
In summary, the data presented here show that post-ischemic hemispheric swelling can be decoupled from infarct volume, and that SUR1-TRPM4 channels, not KATP, mediate postischemic brain swelling.
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